Proteomedix Company
Proteomedix (an Onconetix company; NASDAQ:ONCO) is a healthcare company whose mission is to transform prostate cancer diagnosis. The company has identified novel biomarker signatures with utility in prostate cancer diagnosis, prognosis and therapy management. The lead product Proclarix® is a blood based prostate cancer test panel and risk score currently available in Europe. Proteomedix is located in the Bio-Technopark of Zurich-Schlieren, Switzerland.
Founded Date:
2010-03-01
Last Funding Date:
2021-09-21
Industry:
Quantum Biology
Total Funding:
21349938
Headquarters:
Schlieren,Zurich,Switzerland,Europe
Funding Status:
private
Super Industry:
Quantum Science Applications
Funding Stage:
M&A
Funding Total Value:
21349938
Last Funding Total Usd:
3248335
Last Funding Total Currency:
CHF
Last Funding Total Value:
3000000
Founders:
Christian Brühlmann,Ralph Schiess,Wilhelm Krek
Phone Number:
0041 44 733 40 90